Head to Head Survey: Ocular Therapeutix (OCUL) & Alliqua Biomedical (ALQA)
Ocular Therapeutix (NASDAQ: OCUL) and Alliqua Biomedical (NASDAQ:ALQA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.
This table compares Ocular Therapeutix and Alliqua Biomedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Ocular Therapeutix and Alliqua Biomedical’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ocular Therapeutix||$1.89 million||75.55||-$44.70 million||($2.27)||-2.14|
|Alliqua Biomedical||$18.24 million||0.53||-$28.24 million||($9.63)||-0.20|
Alliqua Biomedical has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Alliqua Biomedical, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
52.9% of Ocular Therapeutix shares are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 15.8% of Alliqua Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Ocular Therapeutix has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Ocular Therapeutix and Alliqua Biomedical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ocular Therapeutix currently has a consensus target price of $20.67, indicating a potential upside of 326.12%. Alliqua Biomedical has a consensus target price of $10.10, indicating a potential upside of 423.32%. Given Alliqua Biomedical’s higher possible upside, analysts clearly believe Alliqua Biomedical is more favorable than Ocular Therapeutix.
Alliqua Biomedical beats Ocular Therapeutix on 8 of the 13 factors compared between the two stocks.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
Alliqua Biomedical Company Profile
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.